Investor presentation
AMANTA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Amanta Healthcare is a niche pharmaceutical company specialising in sterile liquid parenterals (IV fluids, injectables, ophthalmic, respiratory and irrigation solutions) with 30+ years of legacy and 47 products across 120 countries. For FY26, revenue grew 5% YoY to ₹288 Cr, EBITDA rose 6% to ₹63 Cr with margins improving to 22% (vs 21% in FY25), and PAT surged 42% YoY to ₹15 Cr, driven by debt repayment reducing finance costs from ₹28 Cr to ₹21 Cr. The company is aggressively expanding capacity — SteriPort LVP capacity will grow from 6.6 Cr to 11.6 Cr bottles by FY27 and SVP from 20.9 Cr to 31.7 Cr units — with a ₹130 Cr capex programme including a 10.8 MW captive solar plant (₹34.8 Cr) commissioning Q1FY27 to save ₹9 Cr annually. Debt-to-Equity has been cut from 3.50x (FY23) to 1.06x (FY26). Exports account for 32% of revenue with expansion targeted into regulated markets (UK, Latin America, SE Asia, Africa).
Strong profitability momentum with 42% PAT growth and margin expansion reflects effective cost control. Capacity expansion backed by clear capex roadmap positions the company to hit 20%+ revenue CAGR and 25%+ EBITDA margins over the next two years.